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Introduction: The aim of the study is to investigate the activity and
safety of oral talactoferrin (TLF) plus carboplatin and paclitaxel
(C/P) in patients with previously untreated stage IIIB/IV non-small
cell lung cancer.
Methods: Patients (n 110) were randomly assigned to receive C/P
plus either TLF (C/P/T) or placebo (C/P/P). The primary objective
of this exploratory study was assessment of confirmed response rate
(RR) in the prospectively defined evaluable population with a
one-tailed p  0.05. Secondary objectives included assessment of
progression-free survival (PFS), duration of response, overall sur-
vival (OS), and safety.
Results: The trial met the primary end point of improvement in
confirmed RR in the prospectively defined evaluable population.
Compared with the C/P/P group, RR increased in the C/P/T group by
18% (29–47%; p  0.05) and 15% (27–42%; p  0.08) in the
evaluable and intent-to-treat populations, respectively. Compared
with the C/P/P group, the C/P/T group had a longer median PFS (4.2
versus 7.0 months), OS (8.5 versus 10.4 months), and duration of
response (5.5 versus 7.6 months), although the differences were not
statistically significant. Adverse events (AEs) were consistent with
C/P therapy. There were fewer total AEs (472 versus 569; two-tailed
p  0.003) and grade 3/4 AEs (78 versus 105; p  0.05) in the
C/P/T group compared with the C/P/P group.
Conclusion: TLF, in combination with C/P, demonstrated an ap-
parent improvement in RR, PFS, and OS in patients with previously
untreated stage IIIB/IV non-small cell lung cancer and appears to
enhance activity without significant additional toxicity. These results
need to be confirmed in a phase III trial.
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Lung cancer is the leading cause of cancer-related deathsworldwide and accounts for 28% of cancer-related deaths
in the United States.1 Non-small cell lung cancer (NSCLC) is
the most prevalent form of lung cancer constituting 85 to 90%
of lung cancers.1 Despite aggressive treatment, improvement
in long-term patient survival has been slow and an urgent
need for new therapies remains.
Patients with stage IIIB or IV disease have inoperable
or unresectable lesions and are candidates for systemic anti-
cancer therapy and, if appropriate, consideration for clinical
trials. Platinum-based regimens have been associated with
objective responses and improved survival and are a standard
first-line therapy for these patients.2
Talactoferrin alfa (TLF, also known as recombinant
human lactoferrin) is a recombinant glycoprotein isolated
from Aspergillus niger var. awamori. It is structurally similar
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to native human lactoferrin and is known only to differ in its
glycosylation.3,4
TLF is an orally active, immunomodulatory protein with
a novel mechanism of action. After oral administration, TLF
interacts with gut-associated lymphoid tissue, recruiting circu-
lating immature dendritic cells and inducing their maturation. In
vitro studies demonstrate that dendritic cell maturation in the
presence of tumor antigens and lymphoid effector cells induces
strong innate and adaptive immune responses mediated by
anticancer natural killer cells, CD8 lymphocytes, and natural
killer T cells. Such mechanism may result in the activation of
tumor-draining lymph nodes, cellular infiltration of distant tu-
mors, and tumor cell death.5–9 TLF is not systemically bioavail-
able.10,11 It is plausible to speculate that TLF’s initiation of the
immune response in the gut-associated lymphoid tissue—using
a physiologically important pathway that is anatomically distant
from the primary tumor—may help to minimize the effect of the
cancer’s local immunosuppressive defenses.
TLF has demonstrated antitumor activity in animal mod-
els as a single agent and in combination with chemotherapy.7–9
In in vivo studies, oral TLF inhibited tumor growth in squamous
cell and adenocarcinoma tumor models in immunocompetent
mice. In phase I trials in healthy volunteers10 and cancer pa-
tients,11 oral TLF was well tolerated without any drug-related
serious adverse events (SAEs) or grade 3/4 adverse events
(AEs). Doses of 1.5 to 9 g/d were well tolerated without any
dose-limiting toxicities or definition of a maximum tolerated
dose.11 TLF also showed apparent anticancer activity in a 36-
patient phase IB cancer trial.12,13 This trial included 12 NSCLC
patients whose disease had progressed after standard chemother-
apy. The median progression-free survival (PFS) and median
overall survival (OS) among these 12 NSCLC patients were 4.3
and 8.8 months, respectively.
Based on encouraging preclinical and clinical data, we
conducted this randomized, double-blind, placebo-controlled,
multicenter, phase II trial of TLF or placebo in combination
with carboplatin/paclitaxel (C/P) in patients with locally ad-
vanced or metastatic NSCLC who had not received prior
systemic anticancer therapy for NSCLC.
METHODS
Study Objectives
The objectives were to assess whether the addition of
oral TLF to C/P in previously untreated patients with stage
IIIB or IV NSCLC would result in enhanced anticancer
activity and to evaluate the toxicity of this combination.
Patient Population
Eligibility criteria included histologically confirmed stage
IIIB/IV NSCLC by tumor, node, metastasis staging, absence of
previous systemic chemotherapy or biological therapy, the pres-
ence of measurable disease according to RECIST version 1.0, a
performance status of Eastern Cooperative Oncology Group 0 or
1, and adequate organ function.
Exclusion criteria included brain metastases, active
concurrent radiotherapy, prior radiotherapy to indicator sites,
or use of steroids or an investigational agent within 4 weeks
of study. All patients provided written informed consent in
accordance with institutional and governmental regulations.
Materials and Methods
The study was double-blind and placebo-controlled. Pa-
tients were randomly assigned (1:1) to one of two treatment
arms without stratification:
Y Arm 1: Carboplatin (area under the curve, 5.0 mg/ml/
min)  paclitaxel (175 mg/m2); C/P (q 3 weeks  6
cycles)  oral TLF (1.5 g in 15 ml twice daily for three
6-week cycles; C/P/T).
Y Arm 2: C/P at the same doses as in arm 1 oral placebo
(15 ml twice daily for three 6-week cycles; C/P/P).
The rationale for choosing doses of C/P slightly lower
than doses most commonly used in North America was the
lack of prior experience with the combination of TLF and C/P
and because these doses of C/P are commonly used in some
parts of the world and community practices in the United
States. Any C/P dose modifications were to be performed
according to the manufacturer’s instructions for the appropri-
ate agent. A TLF dose of 3 g/d (1.5 g twice daily) was chosen
as the optimum study dose based on active doses in animal
models; prior clinical studies showed no apparent increase in
antitumor activity at higher doses.11,12 C/P was administered
by intravenous infusion once every 3 weeks for up to six
cycles. TLF or placebo were administered orally for up to
three 6-week cycles (35 consecutive days on the study drug
followed by 1 week off the drug), starting from the day after
C/P administration in the first, third, and fifth chemotherapy
cycles. The C/P  TLF or placebo combination was admin-
istered until disease progression but not longer than 18 weeks
(maximum of six 3-week chemotherapy cycles  three 6-week
TLF or placebo cycles). Computed tomography (CT) scans were
performed at 6, 12, and 18 weeks after completion of 2, 4, and
6 cycles of chemotherapy and at 7 and 10 months during the
follow-up period if no disease progression had occurred.
Study End Points and Statistical Analysis
Primary Analysis
The primary efficacy parameter, upon which the sample
size was based, was response rate (RR; partial response [PR] 
complete response) in the evaluable population. RR was
chosen as the primary end point for this study because TLF
was administered in combination with chemotherapy, which
produces responses in patients with advanced or metastatic
NSCLC, and the study was designed to test whether adding
TLF could increase the RR. In addition, this rationale was
supported by preclinical data suggesting antitumor activity in
combination with chemotherapy. All randomized patients
were included in the intent-to-treat (ITT) population. The
prospectively defined evaluable population included patients
who received at least one dose of TLF/placebo in combina-
tion with at least one dose of C/P and had at least one CT scan
after starting study drugs. Response was assessed by CT
according to RECIST version 1.0.14 Responses required a
confirmatory CT scan obtained at least 4 weeks after the first
scan demonstrating a response. All CT readings, including
those by the site radiologist(s), were blinded to treatment
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group. The investigators, who were also blinded, provided
input into determining the response status.
Secondary Efficacy Analyses
PFS was calculated from the date of randomization
until the date of radiological progression or death. OS was
calculated from the date of randomization to the date of
death. Duration of response (DOR) was calculated from the
first date of a response until radiological progression or death.
Safety Analysis
The safety population consisted of all patients who
received at least one dose of study drug. The safety end points
included treatment-emergent and study agent-related AEs,
SAEs, treatment discontinuations due to AEs, and grade 3/4
laboratory abnormalities using the National Cancer Institute
Common Toxicity Criteria (version 2.0).
Statistical Methods
The sample size calculation was based on an assump-
tion of a 40% target overall RR and a 20% null RR. A sample
size of 50 evaluable patients per treatment group in this
exploratory study provided a comparison between the test and
the control group with 75% power and a one-tailed p value of
0.05. This was an exploratory phase II study, and a one-tailed
test was thought to be appropriate in this setting to assess
whether the addition of TLF to chemotherapy could increase
the RR of the combination. Assuming a 10% rate of non-
evaluable patients, the targeted enrollment was approxi-
mately 110 patients. For the RR analysis, where the patient’s
response status was not known, the patient was assumed to
have progressed. The Fisher’s exact test was used for rate
comparisons. The log-rank test was used for comparisons of
PFS, DOR, and OS. As prospectively defined in the protocol,
a one-tailed test was used for all efficacy analyses.
RESULTS
A total of 110 patients, 55 per arm, were enrolled and
treated at 11 Indian sites between February 2004 and August
2005. The two arms appeared to be well balanced for known
prognostic factors at baseline. Demographic characteristics at
baseline are summarized in Table 1.
All 110 randomized patients were included in the ITT
population. The prospectively defined evaluable population in-
cluded all 100 patients who received at least one dose of study
drug and had at least one CT scan after the start of treatment
(scheduled at 6 weeks after the start of study drugs).
Seventy-three patients completed 18 weeks of study
treatment, 40 (73%) and 33 (60%) in the C/P/T and C/P/P
arms, respectively. Patient disposition is summarized in Table
2. The most common reason for discontinuation from the
study before 18 weeks was disease progression, which was
reported in 9% and 18% of patients in the TLF and placebo
arms, respectively. Other reasons for discontinuation in-
cluded an AE (2% TLF; 4% placebo) and consent withdrawal
(4% TLF; 9% placebo). No patient withdrew because of
TLF-related AEs.
Patients in the two arms received similar amounts of
C/P, with 40 (73%) and 34 (62%) patients receiving six
cycles of chemotherapy in the C/P/T and C/P/P arms, respec-
tively. Compliance to TLF/placebo was very high at 97% in
both arms. Compliance was assessed by counting vials re-
turned by patients to the clinic during each visit and the
patient recording vials taken in a diary.
Confirmed RR
The primary efficacy end point, confirmed RR, was
analyzed in the Evaluable and ITT populations (Table 3).
There were more responders in the C/P/T arm (23 PRs)
compared with the C/P/P arm (15 PRs). One patient in the
C/P/T arm with stage IV NSCLC and liver metastasis had a
possible complete response. After treatment, there was a
TABLE 1. Summary of Baseline Patient Characteristics
Talactoferrin
 C/P
(N  55),
n (%)
Placebo
 C/P
(N  55),
n (%)
Overall
(N  110),
n (%)
Age (yr)
Mean 57.3 54 55.6
Median 55.5 56.1 55.9
Gender
Male 43 (78) 46 (84) 89 (81)
Female 12 (22) 9 (16) 21 (19)
Ethnic origin
Asian Indian 55 (100) 55 (100) 110 (100)
NSCLC stage
Stage IIIB 16 (29) 21 (38) 37 (34)
Stage IV 39 (71) 34 (62) 73 (66)
Performance status
ECOG/Zubrod 0 9 (16) 3 (5) 12 (11)
ECOG/Zubrod 1 46 (84) 52 (95) 98 (89)
C/P, carboplatin/paclitaxel; ECOG, Eastern Cooperative Oncology Group; NSCLC,
non-small cell lung cancer.
TABLE 2. Patient Disposition
Talactoferrin
 C/P
(N  55),
n (%)
Placebo
 C/P
(N  55),
n (%)
Total
(N  110),
n (%)
Enrolled 55 (100) 55 (100) 110 (100)
Randomized 55 (100) 55 (100) 110 (100)
Completed 18 wks of treatment 40 (73) 33 (60) 73 (66)
Early treatment discontinuation
(18 wks of treatment)
15 (27) 22 (40) 37 (34)
Reasons for early discontinuation
Patient withdrew consent 2 (4) 5 (9) 7 (6)
Patient lost to follow-up 3 (5) 0 (0) 3 (3)
Adverse event 1 (2) 2 (4) 3 (3)
Death 4 (7) 4 (7) 8 (7)
Disease progression 5 (9) 10 (18) 15 (14)
Other 0 (0) 1 (2) 1 (1)
C/P, carboplatin/paclitaxel.
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small residual fibrotic lesion visible on a CT scan that was not
biopsied. He remained disease free for more than 2 years after
the last dose of study drug. The RR in the 110-patient ITT
patient population increased from 27% (placebo) to 42%
(TLF); p  0.08. The RR in the 100-patient evaluable
population increased from 29 to 47% (p  0.05), meeting the
prespecified level of statistical significance for the primary
end point. The median DOR was 5.5 and 7.6 months in the
C/P/P and C/P/T arms, respectively (hazard ratio [HR] 
0.53; p  0.07).
Progression-Free Survival
In the ITT population, the median PFS in the placebo
and TLF arms was 4.2 and 7 months, respectively (HR 
0.85; p  0.24). In the evaluable population, the median PFS
in the placebo and TLF arms was 4.2 and 7 months, respec-
tively (HR  0.78; p  0.14).
There was an improvement in the PFS rate at 18 weeks
(end of treatment period), with an increase from 40% in the
placebo to 53% in the TLF arm (p  0.13) for the ITT
population and from 43% in the placebo arm to 59% in the
TLF arm (p  0.08) for the evaluable population.
Overall Survival
In the ITT population, median OS increased from 8.5
months in the placebo arm to 10.4 months in the TLF arm
(HR  0.87; p  0.26). The median OS in the evaluable
patients increased from 8.5 months in the placebo arm to 11.3
months in the TLF arm (HR  0.75; p  0.11). The
Kaplan-Meier curves for OS in the ITT and evaluable popu-
lations are shown in Figures 1A, B. Data on second-line and
subsequent treatments are not available.
Safety Results
TLF appeared to be well tolerated. Patients who re-
ceived C/P/T had fewer total AEs, grade 3/4 AEs, AEs related
to study drug, AEs related to chemotherapy, incidence of
SAEs, and discontinuations due to AEs. The most frequent
AEs were consistent with those typically observed in NSCLC
patients undergoing chemotherapy. These included myelo-
toxicity, gastrointestinal (GI) disorders, respiratory disorders,
and alopecia. The most frequently observed grade 3/4 AEs
were myelotoxicity, GI disorders, and respiratory disorders
(Table 4). Two patients in the placebo arm and one patient in
the TLF arm discontinued due to an AE (Table 2).
TABLE 3. Summary of Confirmed Response Rate by
Treatment Group
ITT Population Evaluable Population
Talactoferrin
 C/P
(N  55),
n (%)
Placebo
 C/P
(N  55),
n (%)
Talactoferrin
 C/P
(N  49),
n (%)
Placebo
 C/P
(N  51),
n (%)
PRa 23 (42) 15 (27) 23 (47) 15 (29)
SD 19 (35) 26 (47) 19 (39) 26 (51)
PD 7 (13) 10 (18) 7 (14) 10 (20)
Nonevaluableb 6 (11) 4 (7) — —
CR  PR 23 (42) 15 (27) 23 (47) 15 (29)
pc 0.08 0.05
a One patient in the C/P/T group with stage IV NSCLC and liver metastasis had a
possible complete response. After treatment, there was a small residual fibrotic-
appearing lesion that was not biopsied to prove that it was free of tumor. He remained
disease-free for more than 2 yrs after the last dose of treatment.
b The prospectively defined evaluable patients were those with at least one CT scan
after the start of therapy. Nonevaluable patients included five discontinuations (two and
three in the talactoferrin and placebo arms, respectively) and five deaths (four and one
in the talactoferrin and placebo arms, respectively) before a 6-wk CT scan. The five
early deaths occurred soon after enrollment (6, 7, 12, 13 and 27 d after randomization).
The causes of death included two patients with severe dyspnea, one patient with severe
gastroenteritis that started the day after randomization, one patient with brain metastases
who had a presumed granuloma on the screening head CT scan, and one patient with
acute coronary syndrome. None of the deaths were considered by the investigators to be
related to talactoferrin/placebo.
c One-tailed p value obtained using Fisher’s exact test.
ITT, intent to treat; PR, partial response; SD, stable disease; PD, progressive
disease; CR, complete response; C/P, carboplatin/paclitaxel.
FIGURE 1. Survival curves in the ITT and evaluable populations. A, Overall survival: ITT population (N  110). B, Overall sur-
vival: evaluable population (N  100). ITT, intent-to-treat.
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The total number of AEs reported in the C/P/T arm was
lower than in the C/P/P arm (472 and 569 AEs, respectively;
Table 5). The difference was statistically significant using a
two-tailed two-proportion binomial test (p  0.003). The total
number of grade 3/4 AEs was also lower in the C/P/T arm than
in the C/P/P arm (78 and 105, respectively; p  0.05).
A total of 605 AEs (297 in the TLF arm and 308 in the
placebo arm) were considered to be related to C/P. There
were fewer AEs considered related to study drug; 8 and 22
AEs in the TLF and placebo arm, respectively. None of the
related AEs in the TLF arm were grade 3 or 4.
DISCUSSION
Oral TLF has previously demonstrated anticancer ac-
tivity in animal models, both as a single agent7,9 and in
combination with chemotherapy.8 More recently, single-
agent activity of TLF was observed in a larger (100 patients)
double-blind, placebo-controlled phase II trial in patients
with refractory NSCLC. The addition of oral TLF to standard
supportive care resulted in a 2.4 month, 65% improvement in
median OS (3.7–6.1 months; one-tailed p  0.04) relative to
patients receiving placebo.15 Single-agent activity was also
observed in a phase II trial in renal cell cancer patients who
had failed previous chemotherapy.16
Based on encouraging early data with oral TLF and its
novel immunomodulatory mechanism of action, we initiated
this randomized, double-blind, placebo-controlled phase II
combination trial in NSCLC patients. The trial met its pre-
specified primary end point of a RR improvement in the
prospectively defined evaluable population (one-tailed p 
0.05). Median PFS, OS, and DOR were also longer in the
TLF arm although the differences were not statistically sig-
nificant. The maximum duration of treatment was 18 weeks
as TLF/placebo was discontinued with C/P discontinuation
even in the absence of progression. This limited treatment
duration was appropriate in phase II as the primary end point
was RR and data on single-agent activity were limited at the
time of study design. However, in a follow-on trial designed
to detect improvements in PFS or OS, it would be desirable
to continue TLF/placebo until disease progression, particu-
larly in view of significant OS improvements reported re-
cently with single-agent TLF.15
The median age of patients enrolled in this trial (ap-
proximately 55 years of age) is consistent with that reported
in the literature for Indian patients with NSCLC17 and is
lower than the age of patients typically enrolled in clinical
trials in Western populations.
An additional finding was the fewer number of total
AEs and grade 3/4 AEs observed in the TLF arm. A similar
reduction in AEs and grade 3/4 AEs was also observed in a
second double-blind, placebo-controlled TLF trial—TLF mono-
therapy in patients with refractory NSCLC.15
The majority of the AE reductions were in the four
areas where reductions were expected based on lactoferrin’s
TABLE 5. Selected Body Systems Account for the Majority of the Adverse Events Reduction
All Adverse Events Grade 3/4 Adverse Events
Placebo
 C/P
Talactoferrin
 C/P
AE
Decrease
Placebo
 C/P
Talactoferrin
 C/P
AE
Decrease
All body systemsa 569 472 97 105 78 27
Selected body systems Number of Patients with AEs Number of Patients with AEs
Thoraco-respiratory systemb 20 12 8 10 5 5
Hematologicalc 44 25 19 25 19 6
Diarrhea, loose stools, vomiting 41 29 12 8 1 7
Musculoskeletald 34 19 15 2 1 1
Nervous system disorderse 19 12 7 3 0 3
a Statistically significant decrease in total adverse events (AEs) (p  0.003) and grade 3/4 AEs (p  0.05) were observed by a two-tailed t-test.
b AEs including mainly dyspnoea, pharyngolaryngeal pain, and tachypnoea.
c AEs including mainly cytopenias (anemia, leukopenia, lymphopenia, monocytopenia, neutropenia, and pancytopenia).
d AEs including mainly arthralgia, back pain, and pain in extremity.
e AEs including mainly hypoaesthesia and paraesthesia.
C/P, carboplatin/paclitaxel.
TABLE 4. Grade 3 or 4 Adverse Events Occurring in 2%
of the Population
Talactoferrin  C/P
(N  55),
n (%)
Placebo  C/P
(N  55),
n (%)
Total
(N  110),
n (%)
Hematological
Neutropenia 10 (18) 10 (18) 20 (18)
Leukopenia 5 (9) 6 (11) 11 (10)
Anemia 4 (7) 6 (11) 10 (9)
Thrombocytopenia 5 (9) 1 (2) 6 (5)
Nonhematological
Dyspnea 5 (9) 9 (16) 14 (13)
Diarrhea 0 (0) 6 (11) 6 (5)
Asthenia 0 (0) 4 (7) 4 (4)
Alopecia 3 (5) 1 (2) 4 (4)
Chest pain 1 (2) 2 (4) 3 (3)
Gastroenteritis 2 (4) 1 (2) 3 (3)
Hemoptysis 1 (2) 2 (4) 3 (3)
Hypoesthesia 0 (0) 2 (4) 2 (2)
Fatigue 0 (0) 2 (4) 2 (2)
Vomiting 0 (0) 2 (4) 2 (2)
C/P, carboplatin/paclitaxel.
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biological activities and previously available data. One major
group of AE reductions was in thoraco-respiratory signs and
symptoms, which are largely attributable to the NSCLC
disease process itself. These reductions are consistent with
the apparent anticancer activity observed with TLF.
Other major groups of AE reductions included areas
where lactoferrin has been shown to have protective effects:
(i) hematological; (ii) GI, specifically relating to diarrhea, loose
stools, and vomiting; and (iii) musculoskeletal/neurosensory. As
an immunomodulatory agent, lactoferrin has demonstrated ac-
celeration in the reconstitution of the immune system after
chemotherapy,18 consistent with the reduction in hematological
AEs in NSCLC patients receiving chemotherapy. The GI tract is
an important target organ for cytotoxic chemotherapy. In ani-
mal19 and human20 studies, oral TLF protected the gut against
irritant-induced enteropathy. This GI-protective effect of TLF is
consistent with the reduction noted in some GI toxicities. Fi-
nally, the reductions in musculoskeletal and neurosensory AEs
are consistent with the known anti-inflammatory21 and antino-
ciceptive22,23 activities of TLF. As TLF is not systemically
bioavailable, and the addition of TLF appeared to be associated
with an increase in anticancer activity of the C/P/T combination,
it is unlikely that the reduction in AEs is due to an impact on the
pharmacokinetics of C/P.
The findings reported in this study on patients with
previously untreated advanced or metastatic NSCLC suggest
that addition of oral TLF to C/P chemotherapy results in
enhanced activity without adding to chemotherapy toxicity.
TLF is currently being evaluated in two phase III trials. The
first study, conducted in patients whose disease has failed two
or more previous treatments, has a primary end point of
survival and compares TLF to placebo in patients who are
also receiving best supportive care. The second study is a
first-line NSCLC trial that compares the addition of TLF or
placebo with C/P. Patients may receive up to six cycles of
chemotherapy and if the disease has not progressed after
completion of chemotherapy, TLF or placebo will be contin-
ued until disease progression. The study coprimary end points
are PFS and OS.
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